<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01386073</url>
  </required_header>
  <id_info>
    <org_study_id>Focus2011-001</org_study_id>
    <nct_id>NCT01386073</nct_id>
  </id_info>
  <brief_title>Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity</brief_title>
  <official_title>Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovative Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of FreshKote and Systane for the
      reduction of dry eye signs and symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TBUT</measure>
    <time_frame>Three months</time_frame>
    <description>Test that measures how long it takes for the tears to break up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>Three months</time_frame>
    <description>Vision obtained with the best possible lens correction (glasses or contact lenses)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>FreshKote</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Systane</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FreshKote</intervention_name>
    <description>Three times a day for three months</description>
    <arm_group_label>FreshKote</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systane</intervention_name>
    <description>three times a day for three months</description>
    <arm_group_label>Systane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dry eye patients with Level 2 disease or greater as defined by the Delpi Panel

          -  Tear osmolarity of at least 308 mosm

          -  At least 18 years of age, Male or Female

          -  Willing to provide written informed consent

          -  Likely to complete all study visits

          -  If currently using ocular lubricants, must complete a 10-14 day washout

        Exclusion Criteria:

          -  Presence of any active ocular disease other than dry eye

          -  Use of topical ophthalmic medications

          -  Use of contact lenses during the trial

          -  Pregnant or nursing, or planning a pregnancy. Patients will be asked if they are
             pregnant or may be pregnant and excluded if they answer in the affirmative.

          -  Any known sensitivity to any ingredients of either study drop

          -  Oral anti-inflammatory medications, omega 3 supplements, or doxycycline

          -  Punctal plugs inserted within the last 6 months or less

          -  Uncontrolled systemic disease

          -  Subjects with known sensitivity or inappropriate responsiveness to any of the
             medications used.

          -  Acute or chronic disease or illness that would increase risk or confound study results
             (e.g., uncontrolled diabetes mellitus, immunocompromised, etc.)

          -  Corneal abnormalities (e.g., ecstatic diseases, degenerations, or corneal dystrophies
             of the stroma or endothelium)

          -  Concurrent participation or participation in the last 30 days in any other clinical
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Pepose, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pepose Vision Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitch Jackson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jackson Eye, S.C</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenna Piel</last_name>
    <phone>951-653-5566</phone>
    <email>j.piel@imedsonline.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jackson Eye, S.C</name>
      <address>
        <city>Lake Villa</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Piel</last_name>
      <phone>951-653-5566</phone>
      <email>j.piel@imedsonline.com</email>
    </contact>
    <investigator>
      <last_name>Mitch Jackson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pepose Vision Institute</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Piel</last_name>
      <phone>951-653-5566</phone>
      <email>j.piel@imedsonline.com</email>
    </contact>
    <investigator>
      <last_name>Jay Pepose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <name_title>Melissa Earl</name_title>
    <organization>CRO</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

